List of Excipients in Branded Drug ADZENYS ER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Neos Therapeutics LP	ADZENYS ER	amphetamine	70165-003	CITRIC ACID MONOHYDRATE
Neos Therapeutics LP	ADZENYS ER	amphetamine	70165-003	CORN OIL
Neos Therapeutics LP	ADZENYS ER	amphetamine	70165-003	METHACRYLIC ACID
Neos Therapeutics LP	ADZENYS ER	amphetamine	70165-003	METHYLPARABEN
Neos Therapeutics LP	ADZENYS ER	amphetamine	70165-003	POLYETHYLENE GLYCOL
Neos Therapeutics LP	ADZENYS ER	amphetamine	70165-003	PROPYLENE GLYCOL

ADZENYS ER Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: August 7, 2026

ADZENYS ER is an extended-release oral suspension containing mixed amphetamine salts at 1.25 mg/mL for attention-deficit/hyperactivity disorder. Its commercial differentiation comes from liquid dosing, taste-masked drug particles, once-daily administration, and dose flexibility rather than from a novel active ingredient. The main opportunities are pediatric adherence, pharmacy-compounded substitution risk, authorized-generic development, improved suspension technology, and reformulation into preservative-free or more convenient delivery systems.

What is ADZENYS ER and how does its formulation work?

ADZENYS ER is an FDA-approved extended-release amphetamine oral suspension marketed by Neos Therapeutics and later associated with Aytu Bioscience’s commercial portfolio. FDA approved the product in January 2017 under NDA 208351 for patients six years of age and older with ADHD.[1]

The product contains mixed amphetamine salts equivalent to 1.25 mg of amphetamine base per mL. The suspension is intended for once-daily oral administration and requires dose measurement with an oral dosing device.

ADZENYS ER product profile

Attribute	ADZENYS ER
Active ingredient	Mixed amphetamine salts
Dosage form	Extended-release oral suspension
Strength	1.25 mg/mL
Route	Oral
Primary indication	ADHD
Patient population	Adults and pediatric patients age six and older, subject to labeling
FDA application	NDA 208351
Regulatory classification	Schedule II controlled substance
Administration	Once daily
Key commercial differentiator	Liquid delivery with extended-release drug particles
Primary formulation challenge	Suspending, taste-masking, and releasing amphetamine consistently over time

The formulation is based on drug-containing particles dispersed in a liquid vehicle. The liquid itself does not create the entire extended-release effect. Release control depends substantially on particle coating and matrix design, while the vehicle supports redispersion, palatability, viscosity, and dose uniformity.

Which excipients are used in ADZENYS ER?

The FDA prescribing information identifies excipients that support suspension stability, taste, viscosity, particle coating, and dose delivery. The reported inactive ingredients include colloidal silicon dioxide, ethylcellulose, glycerin, hypromellose, methylcellulose, poloxamer 188, povidone, sodium citrate, sucralose, xanthan gum, and flavoring components.[1]

Excipient or excipient class	Likely formulation function
Ethylcellulose	Water-insoluble release-controlling coating or polymer component
Hypromellose	Film-forming, viscosity, and release-modifying function
Methylcellulose	Suspending and rheology control
Xanthan gum	Suspension viscosity and particle-resettling control
Colloidal silicon dioxide	Rheology modification and suspension stabilization
Poloxamer 188	Wetting and dispersion of drug particles
Povidone	Binder, wetting agent, or particle-processing aid
Glycerin	Humectant, mouthfeel modifier, and vehicle component
Sodium citrate	Buffering and pH control
Sucralose	Sweetness and taste masking
Flavoring	Reduction of amphetamine bitterness and aftertaste

The most commercially important excipient functions are not interchangeable. A sweetener can improve initial taste without eliminating bitterness during the extended residence time of the product in the mouth. A viscosity modifier can improve dose uniformity but increase pouring resistance or make dosing devices harder to clean. A coating polymer can control release but create manufacturing and particle-size constraints.

How does the excipient strategy support commercial differentiation?

ADZENYS ER uses excipients as part of a delivery platform rather than as passive formulation ingredients. The commercial value is concentrated in four areas.

Taste masking

Amphetamine salts have a strong bitter taste. Pediatric liquid products require a taste-masking system that performs during initial contact and aftertaste. Sucralose and flavoring provide sensory masking, while coated particles reduce direct exposure of the active ingredient.

A substitute product that matches the active ingredient but fails on taste may face lower adherence, more administration resistance, and greater caregiver preference for competing products.

Suspension uniformity

A low-dose liquid product must deliver a consistent amount of amphetamine in each measured volume. Sedimentation, caking, particle aggregation, and incomplete redispersion can produce dose variability.

Xanthan gum, methylcellulose, colloidal silicon dioxide, poloxamer 188, and related excipient systems can control particle wetting and suspension behavior. Their commercial importance increases because a liquid product cannot rely on tablet content uniformity alone. The product must remain physically manageable from bottle storage through the final dose.

Extended-release performance

The release profile depends on the drug-particle coating and polymer system. Ethylcellulose and hypromellose are established pharmaceutical polymers, but their concentrations, grades, coating thicknesses, particle-size distributions, and processing conditions can materially affect release.

A generic developer may be able to use different excipients while demonstrating bioequivalence. That possibility reduces the ability to block competition solely through a list of conventional excipients. Protection is stronger when claims cover the interaction of particle structure, polymer coating, release profile, and liquid suspension characteristics.

Dose flexibility

The 1.25 mg/mL concentration allows titration by volume. This is valuable for children who cannot swallow tablets or capsules and for patients who need intermediate doses not available in fixed-strength solid dosage forms.

Dose flexibility creates a commercial tradeoff. Liquid products may improve titration but introduce dosing errors, bottle handling, storage requirements, and the need for a calibrated oral syringe.

What formulation patents protect ADZENYS ER?

Formulation protection for ADZENYS ER is more likely to focus on multiparticulate extended-release systems, coated amphetamine particles, liquid suspension vehicles, taste masking, and manufacturing processes than on the individual excipients.

Conventional excipients such as ethylcellulose, xanthan gum, glycerin, and sucralose generally provide limited standalone patent protection. The defensible claim structure is more likely to involve:

1. A combination of amphetamine particles and release-controlling polymers.
2. Particle-size distribution and coating parameters.
3. Dissolution performance across specified time intervals.
4. Suspension stability and redispersion after storage.
5. Taste-masking architecture.
6. Manufacturing steps used to produce coated particles.
7. A liquid dosage form that maintains dose uniformity over the labeled shelf life.

FDA approval does not establish the scope or enforceability of patent rights. The Orange Book identifies patents and regulatory exclusivities submitted by the NDA holder, but it does not determine whether a claim will survive invalidity or infringement challenges.[2]

Are excipients themselves patentable?

An excipient is rarely the principal source of protection when it is a widely used pharmaceutical material. The commercial barrier usually comes from the selected grade, concentration range, processing sequence, particle architecture, or performance outcome.

For example, a claim directed broadly to "an extended-release suspension containing ethylcellulose" would face substantial prior-art exposure. A narrower claim directed to a specific coated-particle structure that produces a defined amphetamine release profile may have greater value, although it may also be easier to design around.

Trade secrets can be more important than patent claims in this area. Coating conditions, spray rates, inlet temperatures, drying parameters, particle classification, and sensory-screening methods may remain undisclosed and difficult to replicate.

What is the Orange Book status of ADZENYS ER?

ADZENYS ER was approved under NDA 208351. Orange Book status, listed patents, pediatric exclusivity, and any current regulatory exclusivity must be evaluated against the latest FDA Orange Book data rather than inferred from the approval date.[1,2]

The relevant regulatory questions are:

Issue	Commercial relevance
Listed drug product	Establishes the reference product for an ANDA
Listed patents	Determines potential Paragraph IV exposure
Expired patents	Removes one barrier but does not eliminate formulation complexity
Regulatory exclusivity	May delay ANDA approval even if patent barriers are absent
Controlled-substance status	Adds DEA, quota, security, and distribution requirements
Discontinued or supply-limited status	Can change the attractiveness of an ANDA or authorized generic

Because ADZENYS ER is a small-molecule amphetamine product, biosimilar regulation does not apply. Competition would generally arise through an ANDA, an authorized generic, a 505(b)(2) product, or a therapeutically differentiated product.

When does ADZENYS ER lose exclusivity?

The key loss-of-exclusivity date depends on the current Orange Book patent listing and any applicable regulatory exclusivity. FDA approval occurred in 2017, but the approval date alone does not provide a reliable generic-entry date.

A generic developer would need to assess:

• Listed composition and formulation patents.
• Method-of-use patents, if any.
• Patent term adjustments and patent term extension.
• Regulatory exclusivity remaining on the reference product.
• The status of any Paragraph IV certifications.
• Whether the reference product remains commercially available in the relevant market.
• Controlled-substance manufacturing and distribution capacity.

For a liquid extended-release product, patent expiry does not guarantee immediate commercial entry. Bioequivalence, particle characterization, dissolution matching, taste acceptability, container-closure compatibility, and suspension stability can remain development barriers.

Which companies challenge ADZENYS ER and what Paragraph IV risks exist?

Publicly available information must be checked against current FDA litigation and Orange Book records before attributing a Paragraph IV challenge to a specific manufacturer. The commercial challenge set is likely to include generic companies with experience in controlled substances, oral liquids, multiparticulates, or pediatric products.

A Paragraph IV strategy could target:

• Invalidity of broad extended-release formulation claims.
• Non-infringement through a different polymer or coating process.
• Lack of written description or enablement.
• Obviousness based on known amphetamine multiparticulate systems.
• Failure of the listed patent to meet statutory listing requirements.

The reference-product sponsor’s strongest litigation position would generally involve narrow claims tied to measurable formulation attributes, such as particle coating, dissolution, or suspension behavior. Broad claims limited to common excipients would be more exposed to prior art and design-around strategies.

How does ADZENYS ER compare with competing ADHD liquids?

ADZENYS ER competes with liquid and orally disintegrating ADHD products, including Dyanavel XR, Quillivant XR, and Vyvanse oral solution. These products differ in active ingredient, release technology, dosing burden, and abuse-deterrence profile.

Product	Active ingredient	Dosage form	Main formulation proposition
ADZENYS ER	Mixed amphetamine salts	Extended-release suspension	Amphetamine liquid with coated particles and flexible volume dosing
Dyanavel XR	Amphetamine-based product	Extended-release oral suspension	Liquid amphetamine delivery with once-daily dosing
Quillivant XR	Methylphenidate hydrochloride	Extended-release suspension	Liquid methylphenidate for patients unable to swallow solids
Vyvanse oral solution	Lisdexamfetamine	Oral solution	Prodrug-based amphetamine delivery without suspended coated particles

ADZENYS ER has a potential advantage for patients who require mixed amphetamine salts rather than methylphenidate or lisdexamfetamine. Its disadvantages include the operational complexity of a suspension and the need to maintain dose uniformity after storage.

The competitive gap is clearest in products that combine:

• Ready-to-use liquid dosing.
• Minimal shaking or no shaking.
• Lower bitterness.
• A calibrated syringe.
• Small dose increments.
• Stable performance after repeated opening.
• Packaging that limits caregiver handling errors.

What commercial opportunities exist for ADZENYS ER excipients?

Preservative-free reformulation

A preservative-free version could appeal to patients with sensitivity concerns and simplify positioning in pediatric care. The technical tradeoff is microbiological control after opening. A preservative-free product would require robust container-closure performance, validated in-use stability, and a clear discard period.

Improved taste masking

The current excipient platform can be optimized through alternative flavors, sweetener combinations, ion-exchange resins, polymer coatings, or encapsulated particles. Taste improvement has direct commercial value because it can affect acceptance, adherence, and switching from tablets.

Higher-concentration presentation

A higher concentration could reduce administration volume for adolescents and adults. It would also increase the risk of dosing errors and make small titration increments less forgiving. A successful higher-strength product would need a redesigned syringe and clear dose conversion instructions.

Unit-dose packaging

Unit-dose cups, sachets, or premeasured syringes could improve portability and reduce bottle handling. The principal barriers are packaging cost, controlled-substance security, dose stability, and regulatory requirements for a new presentation.

Authorized generic

An authorized generic could preserve volume after patent barriers weaken and compete with ANDA products on supply reliability. For a controlled substance, the sponsor’s manufacturing network, DEA quota allocation, and pharmacy distribution relationships may be as important as the excipient composition.

505(b)(2) reformulation

A 505(b)(2) product could use the ADZENYS ER reference product while pursuing a different concentration, device, flavor system, or administration format. The opportunity is strongest where the modification solves a documented caregiver or patient problem and supports reliance on existing safety and efficacy information.

What manufacturing and intellectual-property barriers affect generic entry?

Manufacturing is a meaningful barrier because the product requires more than blending an active ingredient into a syrup. A competing manufacturer must control:

• Coated-particle size distribution.
• Polymer-coating uniformity.
• Drug loading.
• Particle wetting.
• Suspension rheology.
• Redispersion after storage.
• Dissolution across the labeled shelf life.
• Taste and mouthfeel.
• Container-closure compatibility.
• Controlled-substance security and yield reconciliation.

A generic can use a different excipient system, but it must still meet applicable pharmaceutical quality and bioequivalence standards. Differences in polymer grade or suspending-agent concentration may alter both in vitro dissolution and in vivo exposure.

What is the revenue exposure and market opportunity?

ADZENYS ER revenue is not generally disclosed as a standalone product metric in public company reporting. Its commercial value should therefore be assessed through prescription volume, net price, payer coverage, channel availability, and the broader ADHD liquid market rather than through a separately reported revenue figure.

The highest-value segments are:

1. Children unable to swallow tablets or capsules.
2. Patients requiring fine dose titration.
3. Caregivers seeking once-daily administration.
4. Patients who do not respond adequately to methylphenidate products.
5. Patients who experience adherence problems with solid amphetamine dosage forms.
6. Pharmacies and health systems seeking dependable liquid amphetamine supply.

The principal commercial risks are generic substitution, payer step therapy, controlled-substance supply constraints, competing amphetamine liquids, and a shift toward long-acting solid products with lower handling complexity.

What is the likely generic launch scenario?

A generic launch is most likely to follow one of three paths:

Scenario	Market effect
First ANDA approval after patent or exclusivity clearance	Rapid price erosion and pharmacy substitution
Authorized generic launch by the reference sponsor	Lower-cost competition with potential supply advantage
505(b)(2) differentiated liquid or device	Slower launch but stronger product-level differentiation

The first generic entrant would have the greatest opportunity to secure preferred pharmacy placement, but controlled-substance manufacturing capacity could restrict supply. Multiple entrants would increase substitution pressure and reduce the value of formulation differentiation unless the product has superior taste, stability, or dosing convenience.

Key Takeaways

• ADZENYS ER’s commercial differentiation comes from liquid delivery, extended-release particles, taste masking, and dose flexibility.
• The principal excipient functions are suspension control, polymer-based release control, wetting, buffering, sweetness, and flavor.
• Common excipients provide limited standalone protection. The stronger IP position lies in particle architecture, coating parameters, dissolution, suspension performance, and manufacturing know-how.
• ADZENYS ER is a small-molecule product. Biosimilar risk does not apply.
• Generic risk depends on current Orange Book listings, regulatory exclusivity, Paragraph IV activity, and the technical difficulty of reproducing a stable, palatable, bioequivalent suspension.
• The strongest commercial opportunities are improved taste masking, higher-concentration dosing, preservative-free packaging, unit-dose delivery, and authorized-generic supply.
• Manufacturing capability, DEA controls, quota access, and distribution may materially affect entry even after patent barriers decline.

FAQs

Can a generic use different excipients from ADZENYS ER?

Yes. An ANDA applicant generally can use a different inactive-ingredient system if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is ADZENYS ER protected by a patent on its sweetener or flavor?

Commercial protection is unlikely to depend solely on sucralose or flavoring. Patent value is more likely to arise from the combined formulation, coated particles, release profile, suspension characteristics, or manufacturing process.

Could a preservative-free ADZENYS ER product receive separate market protection?

A materially different presentation could support separate patent claims or a 505(b)(2) regulatory strategy. The strength of that protection would depend on the specific formulation, device, clinical requirements, and current reference-product exclusivity.

Does amphetamine’s Schedule II status prevent generic competition?

No. Schedule II status does not prevent ANDA competition. It increases operational requirements involving DEA registration, quota, security, recordkeeping, controlled-substance distribution, and supply planning.

Which excipient technology offers the greatest commercial upside?

Particle-level taste masking combined with stable, low-viscosity suspension performance offers the clearest opportunity. It directly addresses the two principal liquid-product problems: unpleasant taste and inconsistent dosing after settling.

References

1. U.S. Food and Drug Administration. (2017). ADZENYS ER prescribing information, NDA 208351. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
3. U.S. Food and Drug Administration. (2016). ANDA submissions: Product-specific guidance for industry. FDA.
4. U.S. Food and Drug Administration. (2020). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.
5. Aytu BioScience, Inc. (2021). Annual report and product portfolio disclosures. U.S. Securities and Exchange Commission.